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ABSTRACT 
Purpose 
The aim of the study was to compare long-term respiratory morbidity in children after 
repair of esophageal atresia (EA) or congenital diaphragmatic hernia (CDH).  
 
Patients and methods 
Children were seen at 6, 12, and 24 months and 5 years within a prospective 
longitudinal follow-up program in a tertiary children's hospital. Respiratory morbidity 
and physical condition were evaluated at all moments. At age 5 years, pulmonary 
function and maximal exercise performance were tested. 
 
Results 
In 3 of 23 atresia patients and 10 of 20 hernia patients, bronchopulmonary dysplasia 
was developed. Seventeen atresia and 11 hernia patients had recurrent respiratory tract 
infections mainly in the first years of life. At age 5, 25% of EA and CDH patients 
measured showed reduced forced expiratory volume in 1 second (z-score < −2). Both 
atresia and hernia patients showed impaired growth, with catch-up growth at 5 years in 
patients with EA but not in those with hernia. Maximal exercise performance was 
significantly below normal for both groups.  
 
Conclusions 
Esophageal atresia and CDH are associated with equal risk of long-term respiratory 
morbidity, growth impairment, and disturbed maximal exercise performance. 
Prospective follow-up of EA patients aimed at identifying respiratory problems other 
than tracheomalacia should be an integral part of interdisciplinary follow-up programs.  
  
INTRODUCTION 
Congenital diaphragmatic hernia (CDH) and esophageal atresia (EA) are both severe 
congenital anatomical anomalies requiring neonatal surgery and intensive care 
treatment. Follow-up for children with EA tends to focus on gastrointestinal pathologic 
condition.1-3 Respiratory pathologic condition, however, seems equally important and is 
widely described as related to the variable amount of tracheomalacia. Abnormal 
development of the tracheobronchial tree may contribute to tracheomalacia and 
recurrent atelectasis.4 Mild lung function abnormalities after EA repair have been 
described.5,6 Several cross-sectional studies report secondary morbidity. Up to 50% of 
EA patients were found to have associated anomalies such as cardiac anomalies and 
consequently higher morbidity.7 New treatment modalities such as high-frequency 
oscillation (HFO) ventilation, nitric oxide (NO) administration, and extracorporeal 
membrane oxygenation (ECMO) have improved survival rates in CDH patients.8-10 
Evidence is emerging, however, that better survival coincides with a great deal of 
morbidity.11-17 Long-term pulmonary sequelae in CDH survivors seem to result not only 
from residual lung hypoplasia with persistent pulmonary hypertension but also from 
lung injury induced by ventilatory support.18 Other risk factors for morbidity are large 
diaphragmatic defects, ECMO therapy, and patch repair.16  
 
We hypothesized that children after repair of EA show the same extent of respiratory 
pathologic condition as CDH survivors, although probably of a different nature, with 
different causative mechanisms. The aim of the present study was to describe 
respiratory morbidity in EA and CDH patients with respect to baseline characteristics, 
respiratory tract infections (RTIs), lung function, and maximal exercise performance. In 
addition, we evaluated gastrointestinal morbidity and physical growth because these 
factors may influence the main end points with respect to respiratory morbidity. This is 
the first study to prospectively evaluate respiratory morbidity in EA patients at the age 
of 5 years.   
 
 
METHODS  
This longitudinal, observational, prospective, cohort study consists of repeated 
measurements at 6, 12, and 24 months and at 5 years.  
 
Setting 
The facility used for the study was the Pediatric Surgical Department of the Erasmus 
MC-Sophia Children's Hospital, Rotterdam, the Netherlands. This is the only tertiary 
academic facility in the Southwestern part of the Netherlands equipped for all major 
surgical specialties. The referral area has 4 million inhabitants with 44,000 newborns 
annually.  
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Since 1999, a multidisciplinary team -consisting of a consultant senior pediatric 
surgeon, pediatricians, psychologists, a pediatric physiotherapist, nurses, and a social 
worker- runs a follow-up program for children born with a major anatomical 
malformation and their families. A clinical geneticist was added to the team in 2004. The 
program aims to reduce the overall morbidity associated with these malformations, in 
particular, the index diagnoses as described by Ravitch.19 
 
Patients  
All 68 patients with EA and CDH admitted to the ICU of our department within 7 days 
after birth from January 1999 to February 2003 were eligible for this study. For the 
present study, we excluded data from 4 patients having infections and growth 
impairment as a result of a major syndromal or chromosomal anomaly itself (EA, n = 3, 
2 Down's syndrome and 1 undefined; CDH, n = 1, Wolf-Hirschhorn syndrome). Data of 
the 16 children who died within 6 months were excluded as well. Five families did not 
participate in our follow-up program. Thus, 43 children (82.7% of survivors) completed a 
5-year follow-up (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1 Flowchart showing group composition 
  
Procedure 
The Erasmus MC ethical review board agreed with the study, and written parental 
informed consent was obtained for all subjects. Demographic and medical data were 
collected prospectively from the first day of admission. A clinical geneticist routinely 
evaluated major chromosomal, syndromal and cerebral abnormalities during admission. 
By protocol, the children were seen at ages 6, 12, and 24 months and 5 years, corrected 
for gestational age. Age for the final evaluation ranged from 5 to 6.5 years. 
 
General aspects  
At each time-point, a pediatrician performed a full physical examination including 
neurologic examination according to the method of Touwen.20 A senior pediatric 
surgeon evaluated specific pediatric surgical issues. Weight and height were measured, 
and body mass index (BMI) was calculated. Growth data for the Dutch population served 
as reference values21,22 and standard deviation scores (SDS) were calculated using 
Growth Analyser version 3.5 (Dutch Growth Foundation, Rotterdam, The Netherlands). 
Reference values for Dutch children of Moroccan or Turkish origin were used if 
applicable.23,24 
 
Respiratory morbidity  
The incidence and severity of bronchopulmonary dysplasia (BPD) were recorded 
according to the diagnostic criteria of Jobe and Bancalari.25 
 
At each time-point, therapeutic and prophylactic courses of antibiotic treatment, use of 
inhaled bronchodilators and steroids, and readmissions for RTI were recorded. We 
recorded numbers of RTI during the first, the second, and the third to fifth years, 
respectively. At the age of 5 years, 38 children (EA patients, n = 20, and CDH patients, 
n = 18) performed pulmonary function tests as follows: we obtained flow-volume curves 
before and after bronchodilation with 400 μg of salbutamol and measured the fraction 
of exhaled NO (FENO). Flow-volume curves were measured on a Masterscreen electronic 
spirometer (Jaeger, Würzburg, Germany). Forced expiratory volume in 1 second (FEV1) 
was expressed as percentage predicted. Fraction of exhaled NO was measured online 
according to guidelines from the European Respiratory Society and American Thoracic 
Society using the NIOX analyzer (Aerocrine, Solna, Sweden).26 
 
Maximal exercise performance  
At 5 years, the children performed a graded, maximum exercise test using a motor-
driven treadmill (En Mill, Enraf Nonius, Rotterdam, the Netherlands) programmed for 
increases in angle of inclination and speed according to the Bruce protocol.27 
 
The children were encouraged to perform to voluntary exhaustion. The maximal 
endurance time (in minutes, one decimal) served as criterion of exercise capacity, with 
SDS based on recently established reference values for healthy Dutch children (personal 
communication, van der Cammen-van Zijp, May 2008). Before, during, and at 2 and 5 
minutes after the test, children's heart rate and transcutaneous oxygen saturation were 
monitored with a pulse oximeter (MARS [motion artifact system], type 2001, Respironics 
Novametrix, Murrysville, Pa). Heart rate of at least 185 beats per minute or loss of 
coordination was considered to indicate maximal performance.28 
 
Gastrointestinal morbidity  
Children were evaluated for gastroesophageal reflux (GER) by barium swallow x-ray and 
pH-metry as previously described by Bergmeijer.29,30 Gastrointestinal symptoms, use of 
medication, surgical treatment of reflux, and consultation of a dietician were recorded 
as well.  
 
Data analyses  
Descriptive statistics were calculated for baseline characteristics and outcome variables. 
We performed group comparisons with the Mann-Whitney U test. Growth parameters 
and SDS maximal endurance time were compared with the reference values using 
t-tests for independent samples (1-tailed). Statistical significance was accepted at 5% 
level. SPSS 15.0 for Windows (SPSS, Chicago, Ill) was used for data analyses.  
 
 
RESULTS  
Baseline characteristics for both groups of children are shown in Table 1. All CDH 
patients were born after a gestational age of at least 36 weeks; 4 EA patients were born 
before 36 weeks of gestation at 28, 29, 31, and 33 weeks, respectively. All but one EA 
children underwent primary anastomosis via a lateral thoracotomy within 48 hours. One 
patient had a type A long gap atresia and underwent delayed primary anastomosis after 
3 months. Bronchoscopic evaluation of tracheomalacia during the initial repair was not 
routinely performed. In 15 of the 20 children with CDH (75%), the diaphragmatic defect 
was repaired with a Gore-Tex patch (WL Gore and Associates, Flagstaff, Ariz). Only one 
child had a right-sided CDH (5%). Diaphragmatic repair was by subcostal laparotomy in 
all cases. 
 
In neither group complex heart defects were found. For both groups, the major impact 
of morbidity was during the first year of life; hospital admissions occurred mainly in the 
first 6 months and surgical interventions within the first year. Surgical interventions in 
EA patients comprised mainly dilations of anastomotic esophageal strictures (in 70% of 
EA patients, n = 16, median 2 per patient, range 0 - 9) and Nissen fundoplications 
(n = 8, 34.8%). Aortopexies had not been performed.  
  
Table 1 Baseline characteristics distinguished by CA subgroup 
  EA CDH 
 n = 23 n = 20 
Boys, n (%) 15 (65.2) 12 (54.5) 
Gestational age, mean (SD), wk 37.2 (3.5) 39.2 (1.5) 
Birth weight, mean (SD), kg 2.7 (0.8) 3.4 (0.3) 
Patients without additional (major or minor) CA, n (%) 5 (21.7) 12 (60.0) 
Patients with 1 or more additional major CA, n (%) 6 (26.1) 3 (15.0) 
Patients with 1 or more additional minor CA, n (%) 14 (60.9) 5 (25.0) 
Patients with cardiac anomaly, n (%) (ASD, VSD, Coarctation of aorta) 4 (17.4) 2 (10.0) 
Admission in 1
st
 24 mo, median (range), d  60.0 (11 - 181) 67.5 (15 - 192) 
Surgical interventions in 24 mo, median (range), n 5 (1 - 11) 3 (1 - 6) 
Ventilatory support, median (range), d 3.5 (1 - 44) 19.5 (2 - 62) 
Supplemental oxygen, median (range), d 6.0 (1 - 77) 37.5 (3 - 83) 
Patients with additional medical problems at discharge, n (%) 20 (86.9) 18 (90.0) 
Patients with additional medical problems at 5 y, n (%) 21 (91.3) 18 (90.0) 
Additional medical problems per patient at discharge, median (range) 2 (0 - 12) 2 (0 - 6) 
Additional medical problems per patient at 5 y, median (range) 2 (0 - 7) 2 (0 - 10) 
CA: congenital anomaly, ASD: atrial septal defect, VSD: ventricular septal defect 
 
Additional medical problems at discharge varied from GER (n = 21 EA; n = 18 CDH) to 
atopic eczema and were mainly (> 80% for each group) related to the primary 
congenital anomaly. At discharge, 21 (87%) of EA patients and all CDH patients received 
medication. These figures had dropped to 43.5% and 23.8% at the age of 5 years, 
respectively.  
 
Respiratory morbidity  
All EA patients had been ventilated conventionally. Three children (13%) with severe 
tracheomalacia developed BPD (Table 2), and bronchoscopy was performed only in 
these 3 patients. None of the EA patients received ECMO treatment. 
 
Eight CDH patients (40%) were primarily ventilated with HFO and had been converted 
to conventional ventilation before surgical closure of the diaphragm. Four (33.3%) of the 
conventionally ventilated CDH patients were later converted to HFO ventilation. 
Venoarterial ECMO was performed in 11 CDH patients (55%), starting at a median age 
of 13 (range 5 - 265) hours. Extracorporeal membrane oxygenation was discontinued 
after a median of 168 (72 - 459) hours.  
 
Routine vaccination against respiratory syncytial virus and/or influenza was not 
performed.  
Table 2 Respiratory morbidity in EA and CDH patients during the first 5 years of life 
    EA CDH 
  n = 23 n = 20 
Patients with BPD, n (%) none  19 (82.7) 8 (40.0) 
 mild 1 (4.3) 2 (10.0) 
 moderate 1 (4.3) 2 (10.0) 
 severe 2 (8.7) 8 (40.0) 
Total number of RTI in 5 yrs, median (range)   9 (0 - 27) 7 (0 - 17) 
Patients with > 5 RTI in 5 years, n (%)  17 (73.9) 11 (55.0) 
Number of patients admitted for RTI in 5 years, median (range)  0 (0 - 4) 0 (0 - 1) 
Number of therapeutic courses of antibiotics for RTI, median (range)  3.0 (0 - 17) 3.0 (0 - 8) 
 1st year 1.0 (0 - 6) 1.0 (0 - 4) 
 2nd year 1.0 (0 - 4) 1.0 (0 - 3) 
 3 - 5 years 0.0 (0 - 10) 0.0 (0 - 3) 
Patients treated with prophylactic antibiotics for RTI, n (%)    
 1st year 3 (13.0) 0 
 2nd year 5 (21.7) 3 (15.0) 
 3 - 5 years 6 (26.1) 0 
Use of bronchodilators, n (%)  6 (26.1) 5 (25.0) 
Use of inhaled steroids, n (%)  2 (8.7) 2 (10.0) 
FEV1 before bronchodilation, mean % predicted (range)  85 (69 - 118) n = 12 91 (72 - 122) n = 8 
Patients with abnormal FEV1 (Z-score < -2), n (%)  3 (25.0) 2 (25.0) 
FENO, median parts-per-billion (range)   9.0 (5.0 - 20.4) 5.2 (2.8 - 10.0) 
Table 2 gives details of the respiratory morbidity encountered during the 5 years of 
follow-up. Both EA patients born before 30 weeks of gestation developed BPD; only one 
of them had recurrent RTI. Nine (81.1%) of 11 ECMO-treated CDH patients and one 
other developed moderate or severe BPD. Of these 10, 5 (50%) had recurrent RTI. 
Recurrent RTI were also reported in 6 CDH patients (60%) who had absence of or only 
mild BPD. One prematurely born EA patient and both CDH patients with a cardiac 
anomaly developed BPD. None of them had recurrent RTI.  
Hospitalizations for RTI were rare. Median numbers of RTI are relatively low but show 
wide ranges in both groups.  
 
Spirometry before and after bronchodilation was initiated in 38 patients at 5 years; 5 
patients were not examined because of parental refusal (n = 2), for practical reasons 
(n = 2), or because of mental retardation (n = 1). Most patients, however, failed to 
perform reproducible flow-volume curves. Forced expiratory volume in 1 second and 
FENO were the only 2 reliably obtained lung function parameters (Table 2). In both 
groups, 25% (n = 12 EA, 8 CDH) of patients had abnormally low percentage of predicted 
of FEV1. The median FENO was within the predicted range for (n = 9) EA patients (9.0 
parts-per-billion) and in the lower range of normal for (n = 9) CDH patients (5.2 parts-
per-billion).31 
 
Maximal exercise performance  
One EA patient and 2 CDH patients could not perform the maximal exercise test 
because of neurologic underlying disease such as cerebral palsy. Thus, 22 EA patients 
and 18 CDH patients performed the exercise test. Reliable results could not be obtained 
for 6 EA patients for the following reasons: no maximal exercise performance reached 
(n = 3); balance problems (n = 2); and poor concentration (n = 1). Results for 2 of the 
CDH patients were unreliable because of balance problems or unwillingness to perform 
maximally (n = 1 for each reason).  
 
Both in EA (n = 16) and CDH (n = 16) patients, the maximal exercise tolerance was 
significantly below the norm (mean SDS endurance time, -0.60; p = 0.02, and -0.84; 
p = 0.012, respectively). One EA patient (6.3%) and 2 CDH patients (12.5%) had an 
abnormally low maximal exercise tolerance (ie, maximal endurance time SDS < −2; not 
significant). The median (range) heart rate at maximal exercise was 181 (194 - 148) and 
191 (207 - 146) beats per minute for the EA and CDH group, respectively. Two EA 
patients (12.5%) had a decreased oxygen saturation (ie, ≤ 94%) at maximal exercise (94 
and 93%, respectively). This phenomenon was not observed in any of the CDH patients.  
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Figure 2(a, b, and c) Diagram representing the mean (SD) for height (a), weight (b), and BMI (c) 
across time in CDH and EA patients. Circles and solid lines represent CDH; open triangles and dashed 
lines represent EA. * signals significant deviation from the Dutch norm at the 5% level (p ≤ 0.05), 
** signals significant deviation from this norm at the 0.1% level (p ≤ 0.001) 
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Gastrointestinal morbidity  
In both groups, 20 children were treated conservatively with antacids and prokinetic 
drugs initially. Thirteen EA patients and 11 CDH patients also received an acid secretion 
inhibitor. Eight EA patients (34.8%) and 7 CDH patients (35%), respectively, underwent a 
Nissen fundoplication. For those patients who were treated conservatively, the median 
(range) duration of treatment of GER was 23.11 (0 - 71.7) and 8.0 (0 - 64.9) months in EA 
and CDH, respectively. Patients with EA who underwent a Nissen fundoplication had a 
median number of 9.5 RTI in 5 years (range, 0 - 23) vs 7 (3 - 24) for those treated 
conservatively (NS). Corresponding figures for the CDH patients are 9 (1 - 17) vs 7 
(0 - 14) (NS). There was no significant difference in RTI before or after the Nissen 
fundoplication.  
 
A dietician was consulted for 8 patients in each group.  
 
Physical growth  
Data at 6, 12, 24, and 60 months for both groups are shown in Figure 2. At 5 years of 
age, EA patients seemed to catch up in weight, concomitant with an increase in height 
(Figure 2b and a). The BMI SDS was constant after the first year of life for both groups 
but reached a higher level for EA patients (Figure 2c).  
 
Extracorporeal membrane oxygenation-treated CDH patients had a significantly lower 
height at 6 months, 12 months, and 5 years (p = 0.02, 0.04, and 0.04, respectively), lower 
weight at 12 months and 5 years (p = 0.02 and 0.02, respectively), and lower BMI at 12 
months of age (p = 0.05) than non-ECMO-treated CDH patients.  
 
 
DISCUSSION  
We prospectively evaluated respiratory morbidity and factors interrelating with 
pulmonary disease during the first 5 years in 2 groups of children born with major 
congenital anatomical malformations of the respiratory tract: EA and CDH. Both groups 
showed recurrent respiratory tract infections, abnormally low FEV1 in 25% of patients, 
no increase of FENO levels, and decreased maximal exercise tolerance. In addition, a high 
incidence of GER and impaired physical growth were observed in both groups.  
 
Tracheomalacia associated with EA occurs frequently and may lead to respiratory 
insults.32 Less frequent are RTIs, wheezing, and cough; these findings mainly are derived 
from studies using a cross-sectional design.33-36 Results, especially regarding RTIs, 
therefore may have been influenced by recall bias. Dudley and Phelan37 retrospectively 
evaluated 192 EA survivors and found that 78 children had experienced more than 3 
episodes of bronchitis per year in the first 3 years of life. More recent, Malmström et al34 
showed that 41% of adolescents after repair of EA still had respiratory symptoms, and 
52% had ever had pneumonia or wheezing. Pneumonia in the first years of life may give 
rise to mild lung function abnormalities later in life.38 Our prospectively collected data 
are consistent with these findings. In addition, we showed that these problems might 
negatively affect maximal exercise tolerance. Only 3 EA patients with severe 
tracheomalacia required prolonged ventilation and developed BPD, whereas 10 (50%) 
CDH patients, mainly those treated with ECMO, had moderate to severe BPD according 
to criteria of Jobe and Bancalari.25 We assume, therefore, that different mechanisms are 
involved in persisting respiratory morbidity. In CDH patients, the susceptibility of the 
hypoplastic lungs for artificial ventilatory support is well documented.13,39,40  
 
In both groups, the frequency of RTI at any measurement moment did not differ 
between children who underwent a Nissen fundoplication for GER or those who were 
treated conservatively. We assume that reflux in these patients is not a major 
contributor to RTI.  
 
Interestingly, hospital admissions for RTI were hardly needed, and therapeutic antibiotic 
courses had not always been prescribed. This suggests that many RTIs showed a 
relatively mild course and were of nonbacterial origin.  
 
As sample sizes were limited and numbers of possible contributing factors large, we did 
not perform regression analysis to predict respiratory morbidity. Still, we evaluated 
several factors that might have contributed to RTI. Being rare in either group, cardiac 
anomalies did not seem to influence incidences of RTI within the first 5 years. Because 
50% to 60% of CDH patients showed recurrent RTI irrespective of BPD, we assume that 
extrapulmonary factors may be involved as well. Most patients in either group had 
gastrointestinal problems and impaired physical growth. These factors may well 
contribute to increased susceptibility for RTI. Nevertheless, the impact of 
gastrointestinal problems on RTI in EA patients remains inconclusive so far.34,37,38 
 
Pulmonary function testing proved problematic. For no more than half of the patients 
(n = 20), we could interpret FEV1 before bronchodilation. This revealed airflow 
obstruction in 25% of them. From the literature, it appears that pulmonary function 
testing was successful in 40% to 83% of 5-year-old children.41 
 
Fraction of exhaled NO is known to be associated with eosinophilic airway 
inflammation.31,42 Almost all patients in the present study had normal FENO levels, in line 
with findings by Malmström et al.34 The FENO level was increased in only one CDH 
patient, who showed an atopic constitution. Low or normal FENO levels have also been 
described in children with bronchopulmonary dysplasia,25 which might explain the lower 
median FENO in the CDH patients.  
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Both EA and CDH patients showed lower maximal exercise tolerance compared with 
recently established reference values for healthy Dutch children (personal 
communication, Van der Cammen-van Zijp). Persistent respiratory morbidity and 
impaired growth may contribute to this phenomenon.  
 
In spite of gastrointestinal and nutritional morbidity, especially in the first year for EA 
patients, only 13% of parents consulted with a dietician during the child's first year of 
life. For the CDH patients, failure to thrive remained a problem over time. Lack of catch-
up growth was mainly seen in ECMO-treated CDH patients. We assume that they have 
more severe lung hypoplasia requiring intensive work of breathing. Patch repair, GER, 
and recurrent RTI may also contribute, but our data do not allow for hard conclusions. 
Attempts should be undertaken to improve energy intake as work of breathing may 
require a higher energy intake in CDH and, to a lesser extent, EA patients. 
 
Multidisciplinary follow-up of surgical newborns has hardly been performed so far but 
has recently been advocated by the American Academy of Pediatrics for CDH patients.43 
The groups of Muratore and Friedman,15-17 however, have reported retrospectively 
collected data on pulmonary, gastrointestinal, and neurodevelopmental morbidity in 
CDH patients up to 3 years of age in a multidisciplinary follow-up clinic. It appeared 
that these showed continued pulmonary and gastrointestinal morbidity over the years, 
such as the CDH patients in the present study, who show the same pathologic condition 
up to the age of 5 years.  
 
In conclusion, both EA and CDH patients are at risk for long-term respiratory morbidity, 
disturbed maximal exercise performance, and growth impairment. Prospective 
evaluation of EA patients aimed at identifying other respiratory problems than 
tracheomalacia should be an integral part of postoperative interdisciplinary follow-up 
programs.  
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